Cargando…

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series

Detalles Bibliográficos
Autores principales:	Lambertini, Matteo, Preusser, Matthias, Zielinski, Christoph C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6579570/ https://www.ncbi.nlm.nih.gov/pubmed/31275617 http://dx.doi.org/10.1136/esmoopen-2019-000501

Ejemplares similares

Introducing pro and con discussions in ESMO Open—Cancer Horizons
por: Zielinski, C., et al.
Publicado: (2022)

ESMO Open special series on new emerging targets in cancer immunotherapy
por: Lambertini, Matteo
Publicado: (2020)

ESMO Open—Cancer Horizons and the future of oncology
por: Zielinski, Christoph C
Publicado: (2016)

Introducing a new ESMO Open article series: how I treat side effects of immunotherapy
por: Preusser, Matthias
Publicado: (2019)

CSCO joins ESMO Open—Cancer Horizons
por: Zielinski, Christoph C, et al.
Publicado: (2016)

AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open
por: Zielinski, Christoph C, et al.
Publicado: (2016)

ESMO Open: news in breast cancer 2019
por: Lambertini, Matteo
Publicado: (2020)

CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion
por: Awada, Ahmad, et al.
Publicado: (2019)

One year of ESMO Open: Cancer Horizons—where are we going from here?
por: Zielinski, Christoph
Publicado: (2017)

Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
por: Chardin, Laure, et al.
Publicado: (2021)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
por: Heinzerling, Lucie, et al.
Publicado: (2016)

Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment
por: Morgan, Gilberto, et al.
Publicado: (2020)

ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
por: Hernandez-Cordero, Nicole, et al.
Publicado: (2022)

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
por: Villanueva, Nicolas, et al.
Publicado: (2018)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
por: Le Mercier, Isabelle, et al.
Publicado: (2015)

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
por: Qin, Shuang, et al.
Publicado: (2019)

Beyond PD-L1 Markers for Lung Cancer Immunotherapy
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2019)

PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond
por: Ishida, Yasumasa
Publicado: (2020)

Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
por: Chrétien, Sebastian, et al.
Publicado: (2019)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

Combination of CTLA-4 and PD-1 blockers for treatment of cancer
por: Rotte, Anand
Publicado: (2019)

Beyond PD-1 Immunotherapy in Malignant Melanoma
por: Kwiatkowska, Dominika, et al.
Publicado: (2019)

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
por: Quezada, S A, et al.
Publicado: (2013)

Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
por: Xu, Li, et al.
Publicado: (2022)

CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy
por: Brunner-Weinzierl, Monika C., et al.
Publicado: (2018)

Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review
por: Miller, Peter L., et al.
Publicado: (2020)

Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment
por: Tunger, Antje, et al.
Publicado: (2018)

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
por: Pandey, Pratibha, et al.
Publicado: (2022)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
por: Rohatgi, Anjali, et al.
Publicado: (2021)

Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination
por: Tan, Zhiwu, et al.
Publicado: (2020)

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
por: Ziogas, Dimitrios C., et al.
Publicado: (2023)

Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity
por: Alvarez, Maite, et al.
Publicado: (2019)

Refining patient selection for breast cancer immunotherapy: beyond PD-L1
por: Kossai, M., et al.
Publicado: (2021)

CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers
por: Tuccilli, Chiara, et al.
Publicado: (2018)

A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets
por: Cai, Zongqiang, et al.
Publicado: (2021)

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
por: Zhang, Hao, et al.
Publicado: (2021)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3s7dj0l4ajck6fgpieur44lppt